Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …

Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …

Emerging biologic subsets and new prognostic markers are significantly and adversely
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …

There is an unmet need for effective biological therapies for relapsed central nervous system
(CNS) lymphoma. Lenalidomide is active in activated B-cell type diffuse large B-cell …

Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse
large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively …

Diffuse large B-cell lymphomas with aberrations in MYC, BCL2 and/or BCL6 by genetic
alterations or protein expression represent a group of high grade B-cell lymphomas with …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-
cells. Prognosis is strongly associated with molecular subgroup, although the driver …

Opinion statement Diffuse large B cell lymphoma (DLBCL) arises from extranodal organs in
about 30% of cases. Its prognosis and risk of recurrence in the central nervous system …